Related Experiment Videos
Intracardiac thrombus in murine Coxsackievirus B3 myocarditis
C Kishimoto1, H Ochiai, S Sasayama
1Second Department of Internal Medicine, Faculty of Medicine, Toyama Medical and Pharmaceutical University, Japan.
Insights
Coxsackievirus B3 (CB3) myocarditis increases the risk of intracardiac thrombi. Congestive heart failure (CHF) significantly elevates this risk, highlighting its role in thromboembolism.
Area of Science:
- Cardiology
- Virology
- Pathology
Background:
- Myocarditis, an inflammation of the heart muscle, can lead to serious complications.
- Intracardiac thrombi (blood clots within the heart) are a known risk in cardiac conditions.
- The relationship between coxsackievirus B3 (CB3) myocarditis, congestive heart failure (CHF), and thrombosis requires further elucidation.
Purpose of the Study:
- To investigate the temporal development of intracardiac mural thrombi in a murine model of CB3 myocarditis.
- To determine the association between the presence of CHF and the occurrence of thrombosis in this model.
Main Methods:
- C3H/He mice were inoculated with CB3 to induce myocarditis.
- Mice were observed for 90 days, with periodic sacrifice on days 4, 8, 14, 30, and 90.
- Incidence of CHF and intracardiac thrombi were assessed in the surviving mice.
Main Results:
- Of 129 mice with myocarditis, 35 (27.1%) developed CHF and 40 (31.0%) showed thrombi after day 8.
- Thrombosis incidence was significantly higher in mice with CHF (71.4%) compared to those without CHF (16.0%) (P < 0.001).
Conclusions:
- CB3 myocarditis presents a significant risk for thromboembolic events.
- Congestive heart failure is identified as a critical risk factor for the development of intracardiac thrombi in this model.
Abstract:
We studied the appearance of intracardiac mural thrombi with time and the relationship between thrombosis and congestive heart failure (CHF) in murine coxsackievirus B3 (CB3) myocarditis. Four- to six-week-old C3H/He mice were inoculated intraperitoneally with CB3 and were observed for 90 days. Mice were sacrificed periodically on days 4, 8, 14, 30, and 90. Among 129 mice with myocarditis, 35 (27.1%) developed CHF and 40 (31.0%) demonstrated thrombi after day 8. The total incidence of thrombosis was significantly higher in mice with CHF (71.4%; 25/35) than in those without CHF (16.0%; 15/94) (P less than 0.001). The present study suggests that CB6 myocarditis carries a significant risk of thromboembolism, and that CHF is a risk factor for the appearance of thrombi.